Cargando…

Neuroinflammation in neuronopathic Gaucher disease: Role of microglia and NK cells, biomarkers, and response to substrate reduction therapy

BACKGROUND: Neuronopathic Gaucher disease (nGD) is a rare neurodegenerative disorder caused by biallelic mutations in GBA and buildup of glycosphingolipids in lysosomes. Neuronal injury and cell death are prominent pathological features; however, the role of GBA in individual cell types and involvem...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boddupalli, Chandra Sekhar, Nair, Shiny, Belinsky, Glenn, Gans, Joseph, Teeple, Erin, Nguyen, Tri-Hung, Mehta, Sameet, Guo, Lilu, Kramer, Martin L, Ruan, Jiapeng, Wang, Honggge, Davison, Matthew, Kumar, Dinesh, Vidyadhara, DJ, Zhang, Bailin, Klinger, Katherine, Mistry, Pramod K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	eLife Sciences Publications, Ltd 2022
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381039/ https://www.ncbi.nlm.nih.gov/pubmed/35972072 http://dx.doi.org/10.7554/eLife.79830

Ejemplares similares

The definition of neuronopathic Gaucher disease
por: Schiffmann, Raphael, et al.
Publicado: (2020)

Incremental biomarker and clinical outcomes after switch from enzyme therapy to eliglustat substrate reduction therapy in Gaucher disease
por: Kleytman, Nathaniel, et al.
Publicado: (2021)

Osteonecrosis in Gaucher disease in the era of multiple therapies: Biomarker set for risk stratification from a tertiary referral center
por: Basiri, Mohsen, et al.
Publicado: (2023)

Neuronopathic Gaucher disease: Beyond lysosomal dysfunction
por: Arévalo, Nohela B., et al.
Publicado: (2022)

Burden of caregivers of patients with neuronopathic and non-neuronopathic Gaucher disease in Japan: A survey-based study
por: Koto, Yuta, et al.
Publicado: (2023)

Isofagomine In Vivo Effects in a Neuronopathic Gaucher Disease Mouse
por: Sun, Ying, et al.
Publicado: (2011)

Ambroxol chaperone therapy for neuronopathic Gaucher disease: A pilot study
por: Narita, Aya, et al.
Publicado: (2016)

Identification of a Biomarker in Cerebrospinal Fluid for Neuronopathic Forms of Gaucher Disease
por: Zigdon, Hila, et al.
Publicado: (2015)

Qualitative analysis of patient interviews on the burden of neuronopathic Gaucher disease in Japan
por: Koto, Yuta, et al.
Publicado: (2022)

Successful therapy for protein-losing enteropathy caused by chronic neuronopathic Gaucher disease
por: Mhanni, A.A., et al.
Publicado: (2015)

Correction: Qualitative analysis of patient interviews on the burden of neuronopathic Gaucher disease in Japan
por: Koto, Yuta, et al.
Publicado: (2023)

CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease
por: Marshall, John, et al.
Publicado: (2016)

Combination therapy in a patient with chronic neuronopathic Gaucher disease: a case report
por: Ceravolo, Ferdinando, et al.
Publicado: (2017)

A global neuronopathic gaucher disease registry (GARDIAN): a patient-led initiative
por: Collin-Histed, Tanya, et al.
Publicado: (2023)

Progression of Behavioral and CNS Deficits in a Viable Murine Model of Chronic Neuronopathic Gaucher Disease
por: Dai, Mei, et al.
Publicado: (2016)

Drosophila melanogaster Mutated in its GBA1b Ortholog Recapitulates Neuronopathic Gaucher Disease
por: Cabasso, Or, et al.
Publicado: (2019)

Impact of Gba2 on neuronopathic Gaucher’s disease and α-synuclein accumulation in medaka (Oryzias latipes)
por: Nakanishi, Etsuro, et al.
Publicado: (2021)

Thirty-year clinical outcomes after haematopoietic stem cell transplantation in neuronopathic Gaucher disease
por: Donald, Aimee, et al.
Publicado: (2022)

Neuronopathic Gaucher disease models reveal defects in cell growth promoted by Hippo pathway activation
por: Messelodi, Daria, et al.
Publicado: (2023)

Viable Neuronopathic Gaucher Disease Model in Medaka (Oryzias latipes) Displays Axonal Accumulation of Alpha-Synuclein
por: Uemura, Norihito, et al.
Publicado: (2015)

Imaging of non-neuronopathic Gaucher disease: recent advances in quantitative imaging and comprehensive assessment of disease involvement
por: Degnan, Andrew J., et al.
Publicado: (2019)

Innate immune response in neuronopathic forms of Gaucher disease confers resistance against viral-induced encephalitis
por: Melamed, Sharon, et al.
Publicado: (2020)

In vitro and in vivo effects of Ambroxol chaperone therapy in two Italian patients affected by neuronopathic Gaucher disease and epilepsy
por: Ciana, Giovanni, et al.
Publicado: (2020)

A multifaceted evaluation of microgliosis and differential cellular dysregulation of mammalian target of rapamycin signaling in neuronopathic Gaucher disease
por: Zhang, Zhenting, et al.
Publicado: (2022)

The clinical spectrum of SARS-CoV-2 infection in Gaucher disease: Effect of both a pandemic and a rare disease that disrupts the immune system
por: Narayanan, Praveena, et al.
Publicado: (2022)

Systemic enzyme delivery by blood-brain barrier-penetrating SapC-DOPS nanovesicles for treatment of neuronopathic Gaucher disease
por: Sun, Ying, et al.
Publicado: (2020)

The GBA p.G85E mutation in Korean patients with non-neuronopathic Gaucher disease: founder and neuroprotective effects
por: Kim, Yoo-Mi, et al.
Publicado: (2020)

Elevated Dkk1 Mediates Downregulation of the Canonical Wnt Pathway and Lysosomal Loss in an iPSC Model of Neuronopathic Gaucher Disease
por: Srikanth, Manasa P., et al.
Publicado: (2020)

Pharmacological Chaperones and Coenzyme Q(10) Treatment Improves Mutant β-Glucocerebrosidase Activity and Mitochondrial Function in Neuronopathic Forms of Gaucher Disease
por: de la Mata, Mario, et al.
Publicado: (2015)

Neurobehavioral phenotypes of neuronopathic mucopolysaccharidoses
por: Barone, Rita, et al.
Publicado: (2018)

Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry
por: Rosenbloom, Barry E., et al.
Publicado: (2022)

The mutation spectrum in Indian patients with Gaucher disease
por: Bisariya, Vartika, et al.
Publicado: (2011)

Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites in Gaucher Disease
por: Adhyaru, Kunal, et al.
Publicado: (2022)

Investigating the neurobehavioral symptoms of neuronopathic Hunter syndrome
por: Grant, Nathan
Publicado: (2020)

Gene Therapy for Neuronopathic Mucopolysaccharidoses: State of the Art
por: de Castro, María José, et al.
Publicado: (2021)

Real‐world effectiveness of eliglustat in treatment‐naïve and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry
por: Mistry, Pramod K., et al.
Publicado: (2020)

Systemic AAV9 gene therapy using the synapsin I promoter rescues a mouse model of neuronopathic Gaucher disease but with limited cross-correction potential to astrocytes
por: Massaro, Giulia, et al.
Publicado: (2020)

Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits
por: Sun, Ying, et al.
Publicado: (2010)

Response to: Investigating the neurobehavioral symptoms of neuronopathic Hunter syndrome
por: Eisengart, J.B., et al.
Publicado: (2020)

The nature and impact of neurobehavioral symptoms in neuronopathic Hunter syndrome
por: Eisengart, J.B., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4pvits30ik1f8tu6gd0mgu5do6